Cargando…

Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis

BACKGROUND: The clinical efficacy and safety of SGLT2i in treating patients with type 2 diabetes mellitus and hypertension lack immense data support. OBJECTIVE: To systematically evaluate the clinical efficacy and safety of SGLT2i in patients with type 2 diabetes mellitus and hypertension by collect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qin, Zhou, Siyuan, Liu, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246111/ https://www.ncbi.nlm.nih.gov/pubmed/37280615 http://dx.doi.org/10.1186/s13098-023-01092-z

Ejemplares similares

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
por: Cheng, Lan, et al.
Publicado: (2022)

Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
por: Gebrie, Desye, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND SULFONYLUREA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Pawar, Ajinkya, et al.
Publicado: (2019)

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
por: Chen, Jiao, et al.
Publicado: (2017)

Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
por: Huang, Yuxin, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
por: Musso, Giovanni, et al.
Publicado: (2019)

Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes
por: Bashier, Alaaeldin, et al.
Publicado: (2017)

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
por: Benham, Jamie L., et al.
Publicado: (2021)

SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Shi, Nanjing, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
por: Pinto, Lana Catani, et al.
Publicado: (2015)

Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
por: Anton, Irina Claudia, et al.
Publicado: (2022)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
por: Shuster, Shirley, et al.
Publicado: (2021)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
por: Cho, Hyun A, et al.
Publicado: (2017)

Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes
por: Garcia-Tirado, Jose, et al.
Publicado: (2022)

Efficacy of single-dose cholecalciferol in the blood pressure of patients with type 2 diabetes, hypertension and hypovitaminoses D
por: de Paula, Tatiana P., et al.
Publicado: (2020)

Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient
por: Bell, David S. H.
Publicado: (2015)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
por: Hopf, Maximilian, et al.
Publicado: (2021)

Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
por: Martínez-Vizcaíno, Vicente, et al.
Publicado: (2021)

Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Treatment in Type 1 Diabetes in a Tertiary Care Center in Saudi Arabia
por: Fallatah, Walla, et al.
Publicado: (2022)

The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis
por: Xu, Chunmei, et al.
Publicado: (2022)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
por: Moura, Filipe A., et al.
Publicado: (2023)

Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
por: Chewcharat, Api, et al.
Publicado: (2020)

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
por: Barreto, Joaquim, et al.
Publicado: (2023)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
por: Lorenzi, Maria, et al.
Publicado: (2016)

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis
por: Zou, Cai-Yan, et al.
Publicado: (2019)

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
por: Mirabelli, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_haeluk5g7esb4sqc0qq46pnff3